Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$25.40M$25.40M−19.6% vs Q1 2019 Net Income-$51.58M-$51.58MN/M vs Q1 2019 EPS Diluted-$0.57-$0.57N/M vs Q1 2019 Gross Profit$14,778,000−11.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$32,935,000N/M Free Cash Flowderived-$35,873,000N/M Margins · derivedGross margin58.2%+5.5 pt vs Q1 2019
Operating margin-207.6%−2.9 pt vs Q1 2019
Net margin-203.1%−3.7 pt vs Q1 2019
ended Mar 31, 2020 · filed May 6, 2020 · 36 d after period end